Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05759728
Other study ID # CNA3103-001
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 24, 2023
Est. completion date December 2027

Study information

Verified date March 2024
Source Carina Biotech Limited
Contact Lina T Jablonskis, PhD
Phone + 61 8 7110 0883
Email lina@carinabiotech.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to determine the safety and best response of treatment with CNA3103 (Leucine-rich repeat-containing G protein-coupled receptor 5 [LGR5]-targeted, Autologous Chimeric Antigen Receptor (CAR) -T Cells), for participants with Metastatic Colorectal Cancer. Participants may undergo a pre-screening biopsy procedure to determine expression of LGR5. Participants will undergo screening procedures, including leukapheresis (collection of T cells) and lymphodepletion (chemotherapy), up to 47 days prior to CNA3103 dosing. Participants will receive a single Intravenous dose of CNA3103. Expansion cohorts will open after determination of the maximum tolerated dose and recommended phase 2 dose in the dose escalation stage. Participants will be followed up, monitored and will attend study visits for safety and research related tests and procedures for 2 years until disease progression, unacceptable toxicity or intolerable adverse event/s, death or withdrawal of consent.


Description:

This is a Phase 1/2a, multicenter, open-label study in adult subjects with metastatic colorectal cancer. (CRC). The study will consist of 2 segments: Phase 1 Segment (Dose Escalation): a Bayesian Optimal Interval (BOIN) study design will be used to minimize any risks of exposure to the novel CNA3103 CAR-T cells during dose escalation while determining the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D). A minimum of 3 subjects per cohort will be enrolled at each dose level, with appropriate staggering of subjects within and between dose levels. Phase 2a Segment (Dose Expansion): After determination of the MTD/RP2D, additional subjects will be enrolled and treated with CNA3103 at that dose to further assess the safety, PK, pharmacodynamic, and anti-tumor properties of CNA3103. Based upon safety data of these additional subjects, the Sponsor, in consult with the Investigators, may choose to enroll additional subjects at the same or a different dose.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date December 2027
Est. primary completion date December 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Signed written Informed Consent. - Male and female subjects aged greater than or equal to18 years. - Eastern Cooperative Oncology Group (ECOG) Performance Score 0 to 1. - Histologically or cytologically confirmed metastatic colorectal cancer previously treated with 5-FU, oxaliplatin and irinotecan-based regimens for metastatic disease. - Positive for any level of LGR5 expression in tumor biopsies. - Measurable or evaluable disease per RECIST version 1.1 . - Life expectancy of at least >12 weeks. - Normal organ and marrow function. - No clinically significant abnormalities in urinalysis results at Screening. - No known clinically significant gastrointestinal disease within 28 days prior to enrolment. - No ongoing requirement for anti-diarrheal therapy. - For female subjects of childbearing potential and male subjects with partners of childbearing potential, agreement (by subject and/or partner) to use a highly effective form of contraception and to continue its use for 6 months after the last dose of IP. - Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to CNA3103 administration. Exclusion Criteria: - Inability to comply with study and follow-up procedures. - Women who are pregnant or lactating. - Has BRAF-mutated colorectal cancer. - Has received trifluridine/tipiracil (TAS-102) or regorafenib for metastatic disease. - Treatment with chemotherapy, hormonal therapy, immunotherapy, biologic therapy, or radiation therapy as cancer therapy within 4 weeks prior to the lymphodepletion start date. - Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent in the previous 28 days prior to enrolment. - Have received antibody-based therapies within the previous 28 days or 5 half-lives of the agent, whichever is shorter. - Major surgery, in the previous 4 weeks prior to enrolment. - Clinically detectable third-space fluid collections in the 4 weeks prior to enrolment. - Any uncontrolled medical or psychiatric risk factors which would contraindicate the use or impair the ability of the subject to provide informed consent, receive protocol therapy or may impose excessive risk to the subject. - Known central nervous system (CNS) disease. - Current use of medications that may have the potential of QTc prolongation. - Uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy. - Has a known infection with human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C, alcoholic or other hepatitis, or cirrhosis. - Inability to be venipunctured and/or tolerate venous access. - Second malignancies within 5 years prior to enrollment, except for those with a negligible risk of metastasis or death, such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent. - Active autoimmune disease that is not controlled by non-steroidal anti-inflammatory drugs (NSAIDs), inhaled corticosteroids, or the equivalent of =10 mg/day prednisone. - History of inflammatory bowel disease (active or past) or active peptic ulcer disease. - History of connective tissue disorders. - History of chronic leukemias. - History of previous, whole abdomen radiation therapy (or total pelvic radiation therapy) or more than Grade 1 residual toxicity from previous radiation therapy. - High cardiovascular risk, including, but not limited to, recent coronary stenting or myocardial infarction in the past year - Left ventricular ejection fraction <50%. - Have had a venous thromboembolic event requiring anticoagulation. - Congenital or acquired long QT syndrome. - QTc prolongation. - History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CNA3103: 5 x 10^7 cells
CNA3103: 5 x 10^7 cells - intravenous infusion
CNA3103: 1.5 x 10^8 cells
CNA3103: 1.5 x 10^8 cells - intravenous infusion
CNA3103: 4.5 x 10^8 cells
CNA3103: 4.5 x 10^8 cells - intravenous infusion
CNA3103: 1.5 x 10^9 cells
CNA3103: 1.5 x 10^9 cells - intravenous infusion
CNA3103: 2.5 x 10^7 cells
CNA3103: 2.5 x 10^7 cells - intravenous infusion

Locations

Country Name City State
Australia Carina Biotech Investigators Adelaide South Australia

Sponsors (1)

Lead Sponsor Collaborator
Carina Biotech Limited

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the safety of treatment with CNA3103. Incidence of Treatment-Emergent Adverse Events 24 Months
Primary To determine the overall best response to CNA3103. Best response per Response Evaluation Criteria in Solid Tumors (RECIST). 24 Months
Secondary To determine the recommended Phase 2a dose (RP2D) of CNA3103 Determined by dose limiting toxicities (DLTs) 28 days
Secondary To monitor for replication competent viral construct in blood specimens Viral construct presence will be monitored 24 Months
Secondary To determine the Pharmacokinetics of CNA3103 Levels of CNA3103 cells measured 24 Months
Secondary To determine overall survival Survival will be calculated from the onset of CNA3103 therapy. 24 Months
Secondary Failure to treat Caused by manufacturing issues or patient related issues. 8 Weeks
Secondary To determine progression-free survival Calculated from the onset of therapy to disease progression. 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT03941080 - Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Completed NCT03647839 - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Terminated NCT02316496 - Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study Phase 2
Completed NCT03251612 - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02380443 - AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer Phase 2
Recruiting NCT02149784 - Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients Phase 3
Recruiting NCT01959061 - Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Phase 4
Terminated NCT01668680 - Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma Phase 2
Recruiting NCT05068531 - Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Not yet recruiting NCT04525807 - Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
Completed NCT04482608 - The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Recruiting NCT03193710 - The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved N/A
Recruiting NCT04854213 - PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) N/A
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03142516 - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status Phase 2
Completed NCT03144804 - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT01910610 - Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Phase 3
Recruiting NCT04874207 - Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib Phase 4